Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)


 0.19 (1.75%)

Market Cap$112,962,293

04/27/17  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $10.66 with a 52 week high of $13.98 and a 52 week low of $7.25.

Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)


Read More

Gemphire Therapeutics Announces Presentation at ACC Meeting of Phase 2 Clinical Trial Investigating Effect of Gemcabene on Insulin Sensitization


Read More

Gemphire to Present at the Oppenheimer Annual Healthcare Conference and the H.C. Wainwright NASH Investor Event


Read More

There are currently no events scheduled.